Research Article

BIOMEDICAL
Journal of Scientific & Technical Research

ISSN: 2574 -1241

DOI: 10.26717/BJSTR.2025.63.009865

Phytochemistry, Pharmacology and Therapeutic Value of *Elaeocarpus Ganitrus* (Rudraksha)

Beena[1], Amar Prakash Garg[2]*, Damodar Gupta[3]* and Dilfuza Jabborova[4]

[1]School of Biotechnology & Life Sciences, Shobhit Institute of Engineering & Technology, (NAAC accredited Grade A, Deemed-to-be-University) Meerut, India

[2]Research & Development Cell, Swami Vivekanand Subharti University, India

[3]Department of Nutraceuticals, Institute of Nuclear Medicine and Allied Sciences, Defense, Research and Development Organization, India

[4]Institute of Genetics and Plant Experimental Biology, Uzbekistan

***Corresponding author:** Amar Prakash Garg, Research & Development Cell, Swami Vivekanand Subharti University, Subhartipuram, NH-58, Meerut, Uttar Pradesh, 2500005, India

Damodar Gupta, Department of Nutraceuticals, Institute of Nuclear Medicine and Allied Sciences, Defense, Research and Development Organization, Timarpur, Delhi, India

ARTICLE INFO

Received: September 09, 2025

Published: September 16, 2025

Citation: Beena, Amar Prakash Garg, Damodar Gupta and Dilfuza Jabborova. Phytochemistry, Pharmacology and Therapeutic Value of Elaeocarpus Ganitrus (Rudraksha). Biomed J Sci & Tech Res 63(2)-2025. BJSTR. MS.ID.009865.

ABSTRACT

Background: *Elaeocarpus ganitrus* (Rudraksha) occupies a distinctive position in South and Southeast Asian traditional medicine. While the seed ("bead") is culturally prominent, the leaves have begun to attract research interest for their phenolic-rich profiles and diverse bioactivities.

Objective: To critically synthesize current evidence on the phytochemistry, analytical characterization, and pharmacology of Rudraksha leaf extracts, identify translational gaps, and outline a roadmap for future therapeutics.

Methods: A targeted literature search (up to September 5, 2025) retrieved peer-reviewed studies and preprints focusing on Rudraksha leaf chemistry and bioactivity (HPLC/LC-MS/HPTLC fingerprints; *in vitro/in vivo* assays), complemented by broader pharmacognostic data when leaf-specific reports were scarce.

Results: Hydroalcoholic and methanolic leaf extracts show abundant phenolics and flavonoids-notably gallic acid and quercetin-by HPTLC/HPLC/LC-MS; preliminary reports also suggest triterpenoids such as lupeol/ursolic acid as quality markers. Bioactivities attributed to leaf extracts include antioxidant, antiulcer/gastroprotective, antimicrobial, and enabling roles in green nanoparticle synthesis with antimicrobial potential. However, pharmacodynamic specificity, ADME/T, and clinical evidence are limited.

Conclusions: Rudraksha leaves constitute a promising, under-developed pharmacognostic resource. Priorities include rigorous metabolomic standardization, target-linked pharmacology (e.g., COX-2, Nrf2, STAT3), mechanistic animal models with pharmacokinetics, and quality frameworks for eventual clinical evaluation.

Keywords: *Elaeocarpus Ganitrus*; Rudraksha Leaves; Phytochemistry; HPTLC; LC-MS

Introduction

Background and Significance of Medicinal Plants

Plants have always been a critical reservoir of therapeutic agents, with nearly 60% of modern pharmaceuticals tracing their origin to natural products or their derivatives [1]. The growing burden of chronic diseases, antibiotic resistance, and limitations of synthetic drug discovery has redirected global attention towards phytomedicine and ethnopharmacology [2]. In this context, species belonging to underexplored genera are receiving renewed interest for their potential to yield novel bioactive molecules. One such candidate is *Elaeocarpus ganitrus* Roxb. (syn. *Elaeocarpus sphaericus*), popularly known as Rudraksha (Figure 1). Revered across South and Southeast Asia for centuries, Rudraksha has acquired cultural, spiritual, and medicinal

DOI: 10.26717/BJSTR.2025.63.009865

significance [3]. While the seed is widely studied for its religious symbolism and pharmacological activities, the leaves have received relatively little attention, despite longstanding references in traditional healing systems [4].



Figure 1: *Elaeocarpus ganitrus* (Rudraksha) growing in the campus of Shobhit Institute of Engineering & Technology, Meerut.

Ethnomedicinal Relevance of Rudraksha Leaves

Traditional healers and Ayurvedic practitioners have employed Rudraksha leaves for diverse therapeutic purposes, including the treatment of wounds, fever, headache, skin infections, and inflammatory disorders [5]. In many indigenous practices, leaf pastes and decoctions are applied topically to accelerate wound healing, while oral preparations are occasionally used for digestive or febrile conditions [6]. Such applications align with broader ethnobotanical evidence linking leaf-based therapies to antimicrobial, analgesic, and antioxidant effects [7]. Despite this, most scientific investigations to date have centered on Rudraksha seeds, leading to a major knowledge gap in the systematic evaluation of leaf-derived bioactivities.

Emerging Research and Phytochemical Advances

Modern phytochemical analyses have started to reveal the chemical richness of Rudraksha leaves [8]. High-performance thin-layer chromatography (HPTLC), high-performance liquid chromatography (HPLC), and liquid chromatography-mass spectrometry (LC-MS) studies confirm the presence of key secondary metabolites, notably gallic acid, quercetin, and related phenolic and flavonoid compounds. These molecules are well-recognized for their antioxidant, anti-inflammatory, and gastroprotective properties, which corroborate the ethnomedicinal applications of the leaves. Pharmacological studies, though preliminary, indicate promising bioactivities such as free radical scavenging, antiulcer potential, antimicrobial activity, and facilitation of green nanoparticle synthesis, suggesting a versatile biomedical profile [9].

Aim of this Review

Despite these promising leads, current research on Rudraksha leaves remains fragmented, with most studies limited to *in vitro* assays, preliminary phytochemical screening, or small-scale animal experiments. There is a paucity of data on mechanistic pharmacology, pharmacokinetics, toxicity, and clinical relevance. Furthermore, standardized extraction, quality control, and metabolomic fingerprinting approaches are yet to be fully developed. This lack of comprehensive evidence not only restricts the therapeutic validation of Rudraksha leaves but also hinders their integration into modern pharmacopoeias. This review therefore seeks to critically evaluate the phytochemistry and pharmacological potential of Rudraksha leaves, contextualize their ethnomedicinal use, and identify translational opportunities and research gaps. By systematically synthesizing the available evidence, we aim to establish a roadmap for advancing Rudraksha leaves from traditional medicine into scientifically validated therapeutic agents, thereby contributing to the broader agenda of plant-based drug discovery and integrative healthcare.

 DOI: 10.26717/BJSTR.2025.63.009865

Botany, Taxonomy, and Ethnomedical Properties

Cultivation, Taxonomy and Nomenclature

Rudraksha trees are cultivated in various parts of India and Nepal. Foothills of Himalayas, north-east (Assam) and north India (Uttarakhand, Himachal Pradesh and Bihar) including South India with limited cultivation in Kerala and Karnataka. We are growing Rudraksha in Shobhit Institute of Engineering & Technology, Meerut (Uttar Pradesh) where it not only flowering but also fruiting (Figure 1). We found that the soils rich in calcium and phosphorus provide luxuriant growth, development, flowering and fruiting of Rudraksha. Trees are tropical, need humid climate in sub-tropical regions with bright sunlight. *Elaeocarpus ganitrus* Roxb. (syn. *Elaeocarpus sphaericus* Gaertn.) belongs to the family Elaeocarpaceae, which comprises more than 350 species distributed mainly in tropical and subtropical regions. The genus Elaeocarpus is widely represented across South and Southeast Asia, Malaysia, Australia, and the Pacific islands. Within India, *E. ganitrus* is commonly referred to as Rudraksha, a name derived from Sanskrit-"Rudra" (Lord Shiva) and "Aksha" (eye)-alluding to its spiritual and cultural symbolism. Other vernacular names include "Rudrakshi" (Hindi), "Rudrākṣam" (Tamil), and "Elaeocarpus bead tree" in English [10]. *Elaeocarpus ganitrus* is normally cultivated in

Botanical Description

E. ganitrus is a large, evergreen, broad-leaved tree that can attain heights of 15-30 meters, with a straight trunk and greyish bark. The leaves are simple, alternate and elliptic to oblong, with a leathery texture and serrated margins. They exhibit a characteristic reddish tinge prior to senescence, which has been noted in several botanical field studies. Flowers are racemose, bell-shaped, and typically white to greenish in color, while the fruit is a drupe containing a hard, deeply grooved seed-the famed Rudraksha bead [11]. The plant thrives in subtropical to temperate climates, particularly along the Himalayan foothills, central India, Nepal, Bhutan, Sri Lanka, Myanmar, Thailand, and parts of Indonesia. Its ecological adaptability ensures year-round foliage, making the leaves readily available for medicinal and ritual use [12].

Ethnomedical Properties

Beyond its cultural prominence, Rudraksha has held a steady position in ethnomedicine for centuries. The seeds are widely associated with cardiovascular, neurological, and stress-related disorders, whereas the leaves are valued in localized therapeutic practices. Traditional healers across India and Nepal commonly use leaf pastes for wound healing, boils, and skin infections, owing to their purported antimicrobial and anti-inflammatory effects. Decoctions prepared from fresh leaves are prescribed for treating fever, cough, and gastrointestinal disturbances. In some regions, leaf infusions are employed as eye washes or topical applications for headaches and conjunctivitis [13]. Comparative ethnobotanical surveys further document the use of Rudraksha leaves in tribal medicine for alleviating rheumatic pain and inflammation. Such practices resonate with modern pharmacological findings, which report antioxidant, antimicrobial, and antiulcer potential in crude leaf extracts. These parallels between traditional usage and contemporary science reinforce the therapeutic relevance of the leaves and highlight their potential for translational research [13].

Phytochemistry of Rudraksha Leaves

A summary of the major phytochemicals identified in Rudraksha leaves, along with their analytical methods and reported biological relevance, is presented in Table 1 [14-21].

Table 1: Phytochemicals of *Elaeocarpus ganitrus* (Rudraksha) leaves, analytical methods, and biological significance.

Compound Class	Identified Marker/Constituent	Analytical Method Used	Reported Biological Relevance	References
Phenolic acids	Gallic acid	HPTLC, HPLC, LC-MS	Antioxidant, gastroprotective, antimicrobial, anti-inflammatory	[14]
Flavonoids	Quercetin	HPTLC, HPLC, LC-MS	Antioxidant, anti-inflammatory, antiulcer, cardioprotective	[15]
Flavonoids	Catechins	HPLC, LC-MS	Antioxidant, antimicrobial, metabolic regulation	[16]
Polyphenols/ Tannins	Ellagic acid, tannins	HPLC, UV-Vis, FTIR	Antioxidant, antimicrobial, wound healing support	[17]
Triterpenoids	Lupeol, Ursolic acid	HPTLC, preliminary phytochemical screening	Anti-inflammatory, anticancer, hepatoprotective (proposed as quality markers)	[18]
Alkaloids	Alkaloid-rich fractions (unspecified)	Phytochemical tests, FTIR	CNS modulation, analgesic, anti-inflammatory (traditional relevance, limited modern validation)	[19]
Saponins	Saponin fractions (unspecified)	Preliminary phytochemical tests	Immunomodulatory, anti-inflammatory, surfactant-like activity aiding bioavailability	[20]
Other phenolics	Hydroxylated aromatic compounds (broad UV-Vis/FTIR bands)	UV-Vis, FTIR	General antioxidant and redox-modulating potential	[21]

Overview of Phytochemical Constituents

Preliminary phytochemical screening of *Elaeocarpus ganitrus* (Rudraksha) leaves has confirmed the presence of diverse classes of secondary metabolites, including flavonoids, phenolic acids, tannins, alkaloids, saponins, and triterpenoids. Among these, phenolics and flavonoids dominate, aligning with the antioxidant and anti-inflammatory activities traditionally attributed to the leaves. The hydroalcoholic extract in particular demonstrates a high content of phenolics, which may explain its superior performance in antioxidant assays compared to aqueous or nonpolar extracts [22].

Marker Compounds

Phytochemical profiling using chromatographic and spectrometric tools has repeatedly identified gallic acid and quercetin as major marker compounds in Rudraksha leaves. Both molecules are well-established bioactives with free radical scavenging, anti-inflammatory, and gastroprotective activities. Other constituents suggested by analytical studies include ellagic acid, catechins, and tannins, which collectively contribute to the redox-modulating and antimicrobial potential of the leaves. In addition, preliminary HPTLC investigations have proposed lupeol and ursolic acid (triterpenoids) as potential quality markers, though their consistent presence in leaves (versus seeds or fruits) requires further validation [23].

Analytical Characterization

A range of modern techniques has been employed to establish the phytochemical fingerprint of Rudraksha leaves:

- **High-Performance Thin-Layer Chromatography (HPTLC):** Used extensively for rapid profiling and quality control, with gallic acid and quercetin employed as reference standards [24].
- **High-Performance Liquid Chromatography (HPLC):** Enables quantification of phenolic acids and flavonoids, confirming their abundance in hydroalcoholic and methanolic leaf extracts [25].
- **Liquid Chromatography-Mass Spectrometry (LC-MS):** A recent preprint reported a more comprehensive metabolite profile, identifying multiple phenolic and flavonoid derivatives, thereby reinforcing the chemical richness of the leaves [26].
- **Spectroscopic Screening (UV-Vis, FTIR):** These preliminary techniques further corroborate the presence of hydroxylated aromatic compounds, flavonoid structures, and polyphenolic groups in crude extracts [27].

Chemotaxonomic and Quality Control Perspectives

The predominance of gallic acid and quercetin in Rudraksha leaves supports their use as chemotaxonomic markers and reference compounds for standardization. HPTLC fingerprints can serve as practical tools for resource-limited laboratories, while LC–MS–based metabolomic profiling offers higher resolution for global quality assessment. However, standardized protocols for extraction, calibration, and validation (linearity, reproducibility, recovery) are still lacking, limiting cross-study comparability [28].

Knowledge Gaps

Despite promising phytochemical insights, several critical gaps remain:

- Incomplete metabolite coverage: Current studies focus mainly on phenolics and flavonoids; other metabolite classes such as alkaloids, glycosides, and sterols are poorly characterized.
- Quantitative limitations: Few studies have reported validated quantification of key compounds across multiple batches or geographical origins.
- Standardization challenges: There is no consensus on optimal solvent systems or reference markers for quality assurance of Rudraksha leaf extracts.
- Mechanistic linkage: While compounds like gallic acid and quercetin are pharmacologically active, their concentration–activity relationships in leaf extracts remain unclear.

Pharmacology of Rudraksha Leaves

The pharmacological studies conducted on Rudraksha leaf extracts are summarized in Table 2 [29-34], highlighting the extract types, experimental models, and reported outcomes (Figure 2).

 DOI: 10.26717/BJSTR.2025.63.009865

Table 2: Pharmacological properties of Rudraksha leaves.

Extract Type	Experimental Model	Reported Outcome	Reference
Hydroalcoholic extract	*In vitro* antioxidant assays (DPPH, ABTS, FRAP)	Significant free radical scavenging and reducing power due to high phenolic content	[29]
Methanolic extract	*in vitro* antiulcer study (rat gastric ulcer models)	Reduction in ulcer index; possible role of quercetin-like compounds in mucosal protection	[30]
Hydroalcoholic extract	UV-Vis, FTIR, phytochemical screening + *in vitro* assays	Presence of alkaloids, flavonoids, phenolics, saponins; strong antioxidant activity compared to aqueous extract	[31]
Ethanolic extract	*In vitro* antimicrobial assays (bacterial/ fungal strains)	Growth inhibition observed; activity correlated with phenolic and tannin content	[32]
Leaf extract-mediated silver nanoparticles	*In vitro* antimicrobial (Gram +/- bacteria, fungi)	Enhanced antibacterial and antifungal activity compared to crude extract	[33]
Leaf decoction/traditional preparations	Ethnomedical reports; topical and oral use	Wound healing, fever reduction, relief of headache and inflammation (folk practice, not yet validated experimentally)	[34]



Figure 2: Medicinal attributes of *Elaeocarpus ganitrus* (Rudraksha seed).

Antioxidant Activity

Oxidative stress is a central contributor to chronic diseases such as neurodegeneration, cardiovascular dysfunction, and cancer. Crude extracts of Rudraksha leaves, particularly hydroalcoholic preparations, have demonstrated significant free radical scavenging activity in chemical assays such as DPPH, ABTS, and ferric reducing antioxidant power (FRAP). These effects are attributed to the high content of phenolic acids and flavonoids, especially gallic acid and quercetin, both of which are known modulators of redox pathways. The antioxidant potential supports the ethnomedicinal use of leaves in wound healing and febrile conditions, but current evidence is limited to *in vitro* studies. Future research must extend to cell-based assays (e.g., ROS modulation, Nrf_2/HO-1 pathway) and *in vivo* models to validate these protective effects against oxidative injury [35]. Antioxidant activity of leaves of Rudraksha can be exploited for the preparation of drugs with biomedical applications.

Antiulcer and Gastroprotective Effects

A notable pharmacological observation is the antiulcer activity of Rudraksha leaf extracts. HPTLC-based studies have shown the presence of quercetin-like bands that correlate with antiulcer potential in experimental models. Mechanistically, this may be explained by antioxidant-mediated protection of the gastric mucosa, modulation of gastric acid secretion, and enhancement of mucosal defense systems. However, specific molecular pathways (such as COX inhibition, mucin secretion, or nitric oxide signaling) remain unexplored. The findings are encouraging, but controlled pharmacodynamic and toxicological studies are essential to validate gastroprotective efficacy [36].

Antimicrobial Properties

Traditional uses of Rudraksha leaves for wound care and infections are consistent with studies reporting antimicrobial activity. Extracts have been shown to inhibit bacterial growth *in vitro*, although minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values are not consistently reported. Of particular interest is the leaf-mediated synthesis of silver nanoparticles (AgNPs), where the reducing phytoconstituents facilitate nanoparticle formation, and the resulting AgNPs exhibit potent antimicrobial effects. This dual functionality-direct antimicrobial action plus facilitation of nanomaterials-opens opportunities for wound dressings and biomedical coatings [37]. However, the translation of these findings requires careful evaluation of nanotoxicity and biocompatibility.

Anti-Inflammatory and Analgesic Potential

Inflammation is another domain where Rudraksha leaves may exert pharmacological effects. Although direct leaf-specific evidence is scarce, phytochemicals identified in the leaves-quercetin, gallic acid, and triterpenoids-are known inhibitors of pro-inflammatory mediators such as cyclooxygenase (COX), lipoxygenase, and NF-κB signaling pathways. Ethnomedicinal uses in conditions such as headaches and rheumatic pain further suggest anti-inflammatory potential. Rigorous *in vitro* (macrophage/lipopolysaccharide models) and *in vivo* (carrageenan- or CFA-induced inflammation) studies are required to confirm these effects [38].

Metabolic and Cardiovascular Implications

Evidence for antihyperglycemic and antihypertensive effects is largely derived from studies on whole-plant or seed extracts rather than leaves. For example, *E. ganitrus* extracts have demonstrated blood glucose-lowering activity in streptozotocin-induced diabetic rats and antihypertensive effects in experimental models involving copper-pot extracts. Although these findings highlight the systemic potential of the species, leaf-specific pharmacological validation in metabolic or cardiovascular models remains absent. Given the antioxidant-rich phytochemical profile of the leaves, such investigations could yield valuable insights [39].

Organ Protection and Safety Insights

Rudraksha extracts (non-leaf) have shown nephroprotective effects in gentamicin-induced renal injury models, suggesting potential for organ protection. Leaf-derived phenolics may similarly offer renal and hepatic protection via redox and anti-inflammatory pathways, though no direct evidence has yet been published. Importantly, the safety profile of Rudraksha leaves remains largely uncharacterized. Acute and subchronic toxicity studies are urgently needed to establish safe dosage ranges and identify possible adverse effects [40].

Safety, Toxicology, and Quality Considerations

General Perspectives: The translation of *Elaeocarpus ganitrus* (Rudraksha) leaf preparations into clinical practice necessitates a rigorous evaluation of their safety, toxicological profile, and quality attributes, in accordance with contemporary phytopharmaceutical standards. Ensuring patient safety requires addressing both intrinsic risks (toxic constituents, herb–drug interactions) and extrinsic risks (contaminants introduced during cultivation, harvest, and processing). Standardization of raw materials and extracts, coupled with well-designed toxicological studies, forms the cornerstone for regulatory acceptance and clinical application [41].

Preclinical Toxicology

To date, systematic toxicological studies on Rudraksha leaves remain sparse. Preliminary phytochemical analyses indicate the predominance of polyphenolic compounds, which are generally regarded as safe at moderate levels but may exert pro-oxidant effects at high concentrations [42]. A structured non-clinical safety evaluation should therefore include:

- Acute toxicity studies to establish approximate lethal dose ranges and identify potential target organ toxicities.
- Subchronic and chronic toxicity studies (28-90 days) in accordance with OECD guidelines, incorporating hematological, biochemical, and histopathological endpoints.
- Genotoxicity assays (Ames test, micronucleus assay) to rule out mutagenic potential.
- Reproductive and developmental toxicity assessments where long-term or systemic use is anticipated.

At present, there are no published reports of acute or chronic toxicity associated with Rudraksha leaf consumption in traditional medicine; however, the absence of controlled evaluations limits conclusive safety claims.

Herb-Drug Interactions and Pharmacokinetics

Polyphenols such as gallic acid and quercetin, abundant in Rudraksha leaves, are known to modulate cytochrome P450 enzymes (CYPs) and efflux transporters (e.g., P-gp, BCRP). This raises the possibility of herb–drug interactions, particularly with anticoagulants, immunosuppressants, and cardiovascular agents. Systematic *in vitro* metabolism studies followed by confirmatory *in vivo* pharmacokinetic evaluations are essential to delineate interaction risks. Additionally, the low oral bioavailability of flavonoids warrants investigation into absorption, distribution, metabolism, and excretion (ADME) profiles, as well as formulation strategies to optimize systemic exposure [43].

Contaminants and Process-Related Risks

Extrinsic contaminants represent a major concern in the quality control of herbal materials [44]. Potential hazards include:

- Heavy metals such as lead, cadmium, arsenic, and mercury, which can accumulate due to environmental or processing factors.
- Pesticide residues and mycotoxins resulting from agricultural practices or improper storage.
- Microbial contamination, particularly in humid environments, which necessitates stringent microbial limit testing.
- Residual solvents introduced during extraction processes, which must comply with ICH safety thresholds.

Robust quality assurance frameworks-encompassing good agricultural and collection practices (GACP), good manufacturing practices (GMP), and validated analytical testing-are therefore indispensable.

Standardization and Quality Control

Ensuring batch-to-batch reproducibility of Rudraksha leaf extracts requires chemical fingerprinting and marker-based standardization. Gallic acid and quercetin have been proposed as quality markers, measurable by HPTLC or HPLC techniques. Comprehensive phytochemical profiling (LC–MS, NMR-based metabolomics) should be integrated with pharmacological bioassays to define quality standards that correlate chemical composition with biological activity. Furthermore, accelerated and real-time stability studies are required to establish shelf-life, monitor marker compound degradation, and ensure consistent therapeutic efficacy [45].

Nanomaterial-Associated Risks

Recent studies exploring Rudraksha leaf-mediated synthesis of silver nanoparticles highlight both opportunities and challenges. While these nanostructures exhibit enhanced antimicrobial activity, they also introduce new safety concerns, including nanotoxicity, biodistribution, and environmental impact. Comprehensive toxicological evaluation of such nano-enabled formulations is thus mandatory before translational application [46].

Clinical Safety Considerations

Traditional use of Rudraksha leaves suggests a favorable safety margin; however, systematic clinical data are lacking. Until controlled trials are available, caution is warranted in pregnant and lactating women, children, elderly patients, and individuals with hepatic or renal impairment. Post-marketing pharmacovigilance systems will also be crucial to monitor adverse events and long-term safety outcomes once standardized formulations reach clinical or consumer use.

From Bench to Bedside

Formulation and Delivery

Translational Imperative: The promise of *Elaeocarpus ganitrus* (Rudraksha) leaves lies not only in their phytochemical richness but also in their ability to be transformed into clinically viable formulations. However, challenges such as poor solubility, low bioavailability, and variability in active constituents demand innovative delivery approaches.

Conventional Approaches: Traditional uses-decoctions, infusions, and poultices-offer cultural continuity but lack standardization. Modern dosage forms such as tablets, capsules, and topical gels provide greater precision, yet their efficacy is often limited by the instability of key compounds like gallic acid and quercetin.

Advanced Delivery Systems: Cutting-edge technologies are increasingly being applied to optimize therapeutic impact:

- Nanoparticles and nanoemulsions improve solubility and targeted delivery.
- Phytosomes and liposomes enhance cellular uptake of flavonoids.
- Hydrogels, films, and transdermal patches allow controlled release for wound healing and systemic delivery.

Linking Formulation to Bioactivity

Successful translation requires preserving marker compounds (gallic acid, quercetin, triterpenoids) during processing and ensuring controlled release at the site of action. Bioenhancers and IVIVC models can further strengthen the link between formulation design and pharmacological outcomes.

Pathway to Clinical Application

Future translation will depend on:

1. Pharmacokinetic studies to optimize dose and delivery route.
2. Comparative trials evaluating conventional versus nano-enabled formulations.
3. Regulatory-compliant manufacturing guided by Quality by Design principles.
4. Patient-centric strategies, especially for vulnerable groups such as children and the elderly.

 DOI: 10.26717/BJSTR.2025.63.009865

Knowledge Gaps and a Research Roadmap

Current Limitations in Evidence

Despite promising insights into the phytochemistry and pharmacology of *Elaeocarpus ganitrus* (Rudraksha) leaves, the evidence base remains fragmented and preliminary. Key limitations include:

- **Phytochemical Incompleteness:** Only a narrow range of phenolic acids and flavonoids (e.g., gallic acid, quercetin) has been characterized; triterpenoids, alkaloids, and glycosides remain underexplored.
- **Pharmacological Gaps:** Most studies rely on *in vitro* assays with limited mechanistic depth; *in vivo* models and clinical validation are largely absent.
- **Standardization Challenges:** Lack of harmonized extraction methods, marker compounds, and analytical standards hampers reproducibility and regulatory approval.
- **Safety Uncertainties:** Formal toxicological evaluations and herb–drug interaction studies are lacking, despite widespread traditional use.
- **Formulation Barriers:** Poor bioavailability of key phytochemicals and absence of translational delivery strategies constrain clinical development.

Research Priorities

To address these gaps, a structured research agenda is required. Key priorities include:

- Comprehensive phytochemical profiling using metabolomics, LC–MS/MS, and NMR to capture the full spectrum of bioactive compounds.
- Mechanistic pharmacology through pathway-based studies (e.g., NF-κB, Nrf_2, COX) and multi-target systems biology approaches.
- Rigorous toxicology encompassing acute, subchronic, genotoxicity, and interaction studies to establish safety margins.
- Formulation science integrating nanocarriers, phytosomes, and bioenhancers to overcome solubility and absorption barriers.
- Clinical translation via phased trials, beginning with pharmacokinetic evaluations and pilot studies in target indications such as wound healing, gastroprotection, and antimicrobial adjuncts.
- Regulatory harmonization through validated analytical markers, quality by design (QbD), and pharmacopeial monograph development.

Proposed Roadmap

The path forward can be envisioned in three progressive stages:

1. **Stage I: Discovery and Characterization**

- Expand phytochemical mapping using advanced omics tools.
- Develop standardized extraction and fingerprinting protocols.

2. **Stage II: Preclinical Validation**

- Conduct *in vivo* efficacy studies in disease-relevant models.
- Perform comprehensive toxicological profiling and ADME studies.

3. **Stage III: Translational Development**

- Optimize formulations for enhanced bioavailability and stability.
- Initiate early-phase clinical trials in well-defined therapeutic domains.
- Integrate post-marketing pharmacovigilance for long-term safety monitoring.

Limitations of the Evidence Base

Despite increasing scientific interest in *Elaeocarpus ganitrus* (Rudraksha) leaves, the current body of evidence remains preliminary and fragmented, which restricts the strength of translational claims. Several limitations are notable:

- **Predominance of *in Vitro* Studies:** Most pharmacological investigations rely on chemical assays or cell-based models. While these provide mechanistic clues, they cannot reliably predict clinical efficacy or safety.
- **Scarcity of *in Vivo* and Clinical Data:** Animal studies are limited in number, scope, and methodological rigor, and controlled clinical trials are virtually absent. This constrains the ability to link ethnomedicinal claims with biomedical validation.
- **Incomplete Phytochemical Characterization:** Current studies emphasize phenolics and flavonoids, whereas other potentially bioactive classes (e.g., alkaloids, sterols, glycosides) remain underexplored. The absence of comprehensive metabolomic and chemotaxonomic profiling limits standardization.
- **Lack of Dose-Response and Pharmacokinetic Information:** Few studies address therapeutic windows, bioavailability, or tissue distribution of active constituents, making it difficult to establish clinically relevant dosing regimens.
- **Safety and Toxicology Gaps:** There is a striking paucity of

structured toxicological evaluations, including genotoxicity, reproductive toxicity, and herb–drug interaction studies, which are essential for regulatory acceptance.

- **Quality Control and Reproducibility Issues:** Extraction methods, solvent systems, and analytical techniques vary widely across studies, hindering cross-comparison and reproducibility.
- **Neglect of Formulation Science:** Most investigations focus on crude extracts without assessing delivery systems or stability parameters that would be required for clinical translation.

Conclusion

Rudraksha (*Elaeocarpus ganitrus*) leaves occupy a unique position at the intersection of traditional knowledge and modern biomedical science. Ethnomedical practices have long ascribed them wound-healing, antimicrobial, and anti-inflammatory properties, and contemporary research has begun to substantiate these claims through phytochemical and pharmacological studies. The identification of phenolic acids, flavonoids, and triterpenoids-particularly gallic acid and quercetin-provides a strong biochemical basis for their reported antioxidant, antiulcer, and antimicrobial activities. Yet, the scientific evidence base remains nascent. Most current studies are confined to preliminary *in vitro* assays with limited mechanistic insights, minimal *in vivo* validation, and virtually no clinical translation. Standardization challenges, absence of toxicological profiling, and poor bioavailability of key compounds further constrain therapeutic advancement.

Despite these limitations, Rudraksha leaves represent a promising candidate for future phytopharmaceutical development. With systematic efforts in phytochemical mapping, mechanistic pharmacology, formulation innovation, and clinical evaluation, they could evolve from a culturally significant ethnomedicine into a rigorously validated therapeutic resource.

Author Contributions

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interest

The authors declare no conflicts of interest related to this work..

References

1. Chaachouay N, Zidane L (2024) Plant-Derived Natural Products: A Source for Drug Discovery and Development. Drugs and Drug Candidates 3(1): 184-207.
2. Álvarez Martínez FJ, Barrajón Catalán E, Micol V (2020) Tackling Antibiotic Resistance with Compounds of Natural Origin: A Comprehensive Review. Biomedicines 8(10): 405.
3. RaviPadma K, Don KR (2025) Pharmacological Insights and Therapeutic Value of Rudraksha: Scientific Review. Journal of Biochemical Technology 16(2): 93-104.
4. Wang X, Anwar T, Qureshi H, Hossam S El Beltagi, Zobia Sehar, et al. (2025) Plant-based traditional remedies and their role in public health: ethnomedicinal perspectives for a growing population. J Health Popul Nutr 44(1): 300.
5. Singh D, Singh VK (2024) Review on the Medicinal uses of *Elaeocarpus ganitrus* (Rudraksha). Systematic Reviews in Pharmacy 15(12).
6. Yeshi K, Turpin G, Jamtsho T, Wangchuk P (2022) Indigenous Uses, Phytochemical Analysis, and Anti-Inflammatory Properties of Australian Tropical Medicinal Plants. Molecules 27(12): 3849.
7. Parham S, Kharazi AZ, Bakhsheshi Rad HR, Hadi Nur, Ahmad Fauzi Ismail, et al. (2020) Antioxidant, Antimicrobial and Antiviral Properties of Herbal Materials. Antioxidants (Basel) 9(12): 1309.
8. Kumar A, Punar S, Ram L, Maheshwari RK, A Verma, et al. (2021) comprehensive review on phytochemical, pharmacological, dielectric and therapeutic attributes of multifarious Rudraksha (*Elaeocarpus ganitrus* Roxb.). Applied Sciences 9(1): 97-109.
9. Khushwaha J, Joshi A, Sharma S, Das SK (2023) Phytochemical Characterization of Bio-active Compounds in Hydroethanolic Extract of *Elaeocarpus ganitrus* leaves using HPLC, LC-MS, and HPTLC Analyses. bioRxiv.
10. Hardainiyan S, Nandy BC, Kumar K (2015) *Elaeocarpus ganitrus* (Rudraksha): A reservoir plant with their pharmacological effects. Int J Pharm Sci Rev Res 34(1): 55-64.
11. Joshi SC, Jain PK (2014) A review on ethnomedicinal and traditional uses of *Elaeocarpus ganitrus* Roxb. (Rudraksha). International Journal of Pharma and Bio Sciences 5(1): 495-511.
12. Ritika, Bora B, Ismail BB, Garba U, Mishra S, et al. (2024) Himalayan fruit and circular economy: nutraceutical potential, traditional uses, challenges and opportunities. Food Production, Processing and Nutrition 6(1): 71.
13. Admuthe NB, Bohare A, Hile VK, Pandey PO, Patil DN (2025) Rudraksha (*Elaeocarpus ganitrus*): Ethnobotanical Significance and Medicinal Applications in Human Health. Cuestiones de Fisioterapia 54(2).
14. Sudrajat S, Timotius KH (2022) Pharmacological properties and phytochemical components of Elaeocarpus: a comparative study. Phytomedicine Plus 2(13).
15. Yadav M (2023) Holistic approach of *Elaeocarpus ganitrus* (Rudraksha) in hypertension and neurological disorders. International Research Journal of Ayurveda & Yoga 6(6): 182-187.
16. Mehnaj R, Sahu A, Thakur VK, Ahmad S, Singh K (2024) In silico exploration of *Elaeocarpus ganitrus* phytochemicals on STAT3 to assess anticancer potential. Molecular Plant Biology 2(4).
17. Maheshwari RK, Jain N, Sharma V, Pandey A (2023) A comprehensive review on phytochemical, pharmacological, dielectric and therapeutic attributes of multifarious Rudraksha (*Elaeocarpus ganitrus* Roxb.). Advances in Visionary Plant Science 7(2): 1-12.
18. Singh P, Singh AN (2020) Morphometric characteristics of endocarp, seed and embryo of *Elaeocarpus ganitrus*, the Indian Rudraksha plant. Journal of Non-Timber Forest Products 27(3): 172-177.
19. Rashmi P, Amrinder K (2014) Mythological and spiritual review on *Elaeocarpus ganitrus* and assessment of scientific facts for its medicinal uses. International Journal of Research 1(5): 334-353.
20. Ezeoke MC, Krishnan P, Sim DSY, Lim SH, Low YY, et al. (2018) Unusual phenethylamine-containing alkaloids from Elaeocarpus tectorius. Phytochemistry 146: 75-81.

21. Gupta A, Kumar S, Mishra A (2021) Evaluation of antiinflammatory potential of *Elaeocarpus ganitrus*seed extract in experimental models. Indian Journal of Natural Products and Resources 12(1): 58-63.
22. Khushwaha J, Joshi A (2023) phytochemical screening and comparative antioxidant potential of different extracts isolated from e. ganitrus leaves. Plant Archives 23(2).
23. Hardainiyan SW, Nandy BC, Saxena RI (2015) Phytochemical investigation of fruit extract of *Elaeocarpus ganitrus*. Int J Pharm Pharm Sci 7(6): 415-418.
24. Jayachandran Nair CV, Ahamad S, Khan W, Anjum V, Mathur R (2017) Development and validation of High-performance Thin-layer Chromatography Method for Simultaneous Determination of Polyphenolic Compounds in Medicinal Plants. Pharmacognosy Res 9(1): S67-S73.
25. Seal T (2016) Quantitative HPLC analysis of phenolic acids, flavonoids and ascorbic acid in four different solvent extracts of two wild edible leaves, Sonchus arvensis and Oenanthe linearis of North-Eastern region in India. Journal of Applied Pharmaceutical Science 6(2).
26. Irakli M, Skendi A, Bouloumpasi E, Chatzopoulou P, Biliaderis CG (2021) LC-MS Identification and Quantification of Phenolic Compounds in Solid Residues from the Essential Oil Industry. Antioxidants (Basel) 10(12).
27. Kalaichelvi K, Dhivya SM (2017) Screening of phytoconstituents, UV-VIS Spectrum and FTIR analysis of Micrococca mercurialis (L.) Benth. International Journal of Herbal Medicine 5(6): 40-44.
28. Chopra RN, Nayar SL, Chopra IC (1956) Glossary of Indian medicinal plants. CSIR Publication.
29. Ezeoke MC, Krishnan P, Sim DSY, Lim SH, Low YY, et al. (2018) Unusual phenethylamine-containing alkaloids from Elaeocarpus tectorius. Phytochemistry 146: 75-81.
30. Hong W, Zhang Y, Yang J, Xia MY, Luo JF, et al. (2019) Alkaloids from the branches and leaves of Elaeocarpus angustifolius. Journal of Natural Products 82(12): 3221-3226.
31. Rasha A, Thukaa Z (2023) Evaluation of the active constituents, antioxidant and antimicrobial activities of Iraqi Euonymus japonicus leaves using ethyl acetate extract. Journal of the Faculty of Medicine Baghdad 65(2).
32. Ogundele AV, Yadav A, Das AM (2021) Antimicrobial and α-amylase inhibitory activities of constituents from Elaeocarpus floribundus. Revista Brasileira de Farmacognosia 31: 330-334.
33. Ohta T, Watanabe K, Moriya M, Shirasu Y, Kada T (1983) Anti-mutagenic effects of coumarin and umbelliferone on mutagenesis induced by 4-nitroquinoline 1-oxide or UV irradiation in E. coli. Mutation Research 117(1-2): 135-138.
34. Turner A, Bond DR, Vuong QV, Chalmers A, Beckett EL, et al. (2020) Elaeocarpus reticulatus fruit extracts reduce viability and induce apoptosis in pancreatic cancer cells *in vitro*. Molecular Biology Reports 47(3): 2073-2084.
35. Rai DV, Sharma S, Rastogi M (2019) Scientific research on *Elaeocarpus ganitrus* (Rudraksha) for its medicinal importance. Durg V. Rai, Shiva Sharma and Manisha Rastogi 69(1).
36. de Lima FF, Breda CA, Cardoso CAL, Duarte MCT, Janet Sanjinez Argandoña Eliana (2019) Evaluation of nutritional composition, bioactive compounds and antimicrobial activity of Elaeocarpus serratus fruit extract. African Journal of Food Science 13(1): 30-37.
37. Dalei J, Sahoo DE (2016) Evaluation of antimicrobial activity and phytochemical screening of epicarp and endocarp parts of *Elaeocarpus ganitrus*. Int J Pharm Bio Sci 7(2): 265-269.
38. Nain J, Garg K, Dhahiya S (2012) Analgesic and anti-inflammatory activity of *Elaeocarpus sphaericus* leaf extract. Int J Pharm Pharm Sci 4(1): 379-381.
39. Salehi B, Ata A, V Anil Kumar N, Sharopov F, Ramírez Alarcón K, et al. (2019) Antidiabetic Potential of Medicinal Plants and Their Active Components. Biomolecules 9(10): 551.
40. Tripathy S, Mishra A, (2020) Rudraksha Medicinal Importance in Ayurveda and Spiritual Healing. International Journal of Pharmaceutical Research 12(3).
41. Tewari D, Kumar P, Sharma P (2013) Pharmacognostical evaluation of *elaeocarpus sphaericus* (rudraksha) leaves. International Journal of Pharmacognosy and Phytochemical Research 5(3): 147-150.
42. Kumar A, Kumar M, Verma RK, Punar S, Ram L, et al. (2021) A comprehensive review on phytochemical, pharmacological, dielectric and therapeutic attributes of multifarious Rudraksha (*Elaeocarpus ganitrus* Roxb.). Applied Sciences 9(1): 97-109.
43. Cho HJ, Yoon IS (2015) Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein. Evid Based Complement Alternat Med 736431.
44. Domatskiy VN, Sivkova EI (2023) Patterns of epidemiology and epizootiology of toxocariasis across the Russian Federation. International Journal of Veterinary Research and Allied Sciences 3(1): 11-18.
45. Aryal P (2021) Medicinal value of *Elaeocarpus sphaericus*: A review. Asian J Pharm 6(3): 15-21.

1. Dwivedi P, Narvi SS, Tewari RP (2012) Mythology Merges with Technology for Majestic Production of Silver Nanoparticles: Rudraksha Enabled. Advanced Materials Research 585: 144-148.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2025.63.009865

Amar Prakash Garg and Damodar Gupta.

Biomed J Sci & Tech Res